-- Euroz Hartleys週一在一份報告中指出，Amplitude Energy（ASX：AEL）東海岸供應項目鑽探工作的重啟將成為下半年市場關注的焦點，而Orbost油田產能進一步提升以及Otway/Cooper盆地產量增加帶來的額外利好，有望推動該公司2026財年第四季度業績創歷史新高。 Amplitude公佈的第三財季產量為6.9拍焦耳當量，高於去年同期的6.1拍焦耳當量。該公司也公佈了3月份季度的銷售量為6.8拍焦耳當量，高於去年同期的6拍焦耳當量，同時季度營收也創下歷史新高，達到7410萬澳元，而去年同期為6340萬澳元。 受夏季/秋季淡季期間南部市場住宅需求下降以及昆士蘭州供應量增加導致本季現貨市場價格走軟的影響，該公司營收比市場預期低約10%。 該投資公司維持對Amplitude Energy的「買進」評等和3.25澳幣的目標價，但將目標價列入待定名單。 Amplitude Energy的股價在周一的交易中下跌了5%。
Related Articles
Research
Mizuho Downgrades Adobe to Neutral From Outperform, Adjusts Price Target to $270 From $315
Adobe (ADBE) has an average rating of overweight and mean price target of $321.05, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$ADBE
Treasury
US Treasury Yields Edge Up Pre-Bell as Iran's Hormuz Offer Delinks Deal With Nuclear Talks
US Markets
Organon Agrees to Be Acquired by Sun Pharmaceutical in $11.75 Billion Deal
Organon (OGN) shares spiked early Monday after the healthcare company agreed to be acquired by Indian pharmaceutical firm Sun Pharmaceutical Industries in an all-cash deal with an enterprise value of about $11.75 billion.Shareholders of Organon will receive $14 a share in cash under the terms of the transaction, the companies said in a joint statement on Sunday. Organon's stock jumped 15% in the most recent premarket activity."Following a comprehensive review of strategic alternatives, our board determined that this all-cash transaction offers compelling and immediate value to Organon stockholders," Organon Chief Executive Carrie Cox said in the statement. "We believe Sun Pharma is well positioned to support Organon's businesses, employees and patients globally."Organon, which focuses on women's health, was formed in 2021 following its separation from pharmaceutical giant Merck (MRK).The deal, which requires approval from regulators and clearance from Organon's shareholders, is expected to complete early next year."This transaction is a logical next step in strengthening Sun Pharma's global business," according to Sun Pharma Managing Director Kirti Ganorkar. "In addition, there is a scope for synergies including significant revenue upside opportunities to be realized over the coming years."Sun Pharma intends to fund the acquisition through a combination of available cash resources and committed financing from banks. The Indian company anticipates the transaction to allow it to enter the biosimilar market.For the year ended Dec. 31, Organon reported revenue of $6.22 billion and adjusted earnings before interest, taxes, depreciation and amortization of $1.91 billion. In February, the company said it expected revenue of $6.2 billion for the current year, while five analysts polled by FactSet estimate $6.15 billion.
$OGN